Literature DB >> 11014951

Use of intramuscular progesterone versus intravenous albumin for the prevention of ovarian hyperstimulation syndrome.

L Costabile1, V Unfer, C Manna, S Gerli, D Rossetti, G C Di Renzo.   

Abstract

This study was designed to compare the effectiveness of intramuscular progesterone with that of intravenous albumin in the prevention of ovarian hyperstimulation syndrome (OHSS). Ninety-six patients at high risk to develop OHSS (estradiol concentration >9, 000 pmol/l on the day of hCG administration and over 20 follicles of a diameter larger than 14 mm observed by transvaginal ultrasonography) and undergoing in vitro fertilization-embryo transfer were enrolled. They were randomly treated with intramuscular progesterone (200 mg/day) or 100 ml of 20% intravenous albumin in order to estimate the difference in the incidence of OHSS. A significant difference in the incidence of moderate OHSS and no cases of severe OHSS were observed between the groups. Our data show the effectiveness in preventing OHSS with high doses of progesterone. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014951     DOI: 10.1159/000010306

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  3 in total

1.  Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.

Authors:  Ensieh Shahrokh Tehraninejad; Maryam Hafezi; Arezoo Arabipoor; Elham Aziminekoo; Mohammad Chehrazi; Akram Bahmanabadi
Journal:  J Assist Reprod Genet       Date:  2012-01-10       Impact factor: 3.412

2.  Co action of CFTR and AQP1 increases permeability of peritoneal epithelial cells on estrogen-induced ovarian hyper stimulation syndrome.

Authors:  Pei-Yin Jin; Yong-Chao Lu; Ling Li; Qin-Fu Han
Journal:  BMC Cell Biol       Date:  2012-08-28       Impact factor: 4.241

Review 3.  Volume expanders for the prevention of ovarian hyperstimulation syndrome.

Authors:  Mohamed A Youssef; Selma Mourad
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.